Different indications, Warnings and precautions, and contraindications for the same drug-an international comparison of prescribing information for commonly used psychiatric drugs

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 3, 2013, Pages 329-333

  Pfistermeister, Barbara ^a   Schenk, Christian ^a   Kornhuber, Johannes ^b   Bürkle, Thomas ^a   Fromm, Martin F ^a   Maas, Renke ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Antidepressive agents; International comparison; Pharmacoepidemiology; Prescribing information; Serotonin agents; Summary of Product Characteristics

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; CITALOPRAM; DOXEPIN; FLUOXETINE; METHYLPHENIDATE; MIRTAZAPINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ARTICLE; CLINICAL PHARMACY; DEPRESSION; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG SAFETY; HUMAN; INFORMATION PROCESSING; MENTAL DISEASE; NOCTURNAL ENURESIS; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; STANDARDIZATION;

CONSENSUS; COOPERATIVE BEHAVIOR; DRUG LABELING; DRUG UTILIZATION; EUROPE; GUIDELINE ADHERENCE; HUMANS; INTERNATIONAL COOPERATION; PATIENT SAFETY; PHARMACOEPIDEMIOLOGY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PSYCHOTROPIC DRUGS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84874531344     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3389     Document Type: Article

References (12)

1. Nutt DJ, Davidson JR, Gelenberg AJ, et al. International consensus statement on major depressive disorder. J Clin Psychiatry 2010; 71(Suppl E1): e08.
2. Fernandez A, Haro JM, Martinez-Alonso M et al. Treatment adequacy for anxiety and depressive disorders in six European countries. Br J Psychiatry 2007; 190: 172-173.
3. Bergk V, Haefeli WE, Gasse C, et al. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol 2005; 61: 327-335.
4. Reggi V, Balocco-Mattavelli R, Bonati M, et al. Prescribing information in 26 countries: a comparative study. Eur J Clin Pharmacol 2003; 59: 263-270.
5. Lohse, M, Müller-Oerlinghausen B Psychopharmaka. In Schwabe U, Paffrath D (eds.). Arzneiverordnungs-Report 2011. Springer: Berlin Heidelberg, 2011.
6. WHO. Definition and general considerations. WHO Collaborating Centre for Drug Statistics Methodology, Oslo; December 2009. http://www.whocc.no/ddd/definition_and_general_considera/ (accessed 27 August 2012).
7. Vitry AI. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 2007; 63: 709-714.
8. Rougemont M, Ulrich S, Hiemke C, et al. French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs. Fundam Clin Pharmacol 2010; 24: 377-384.
9. Wall AJ, Bateman DN, Waring WS Variability in the quality of overdose advice in summary of product characteristics (SPC) documents: gut decontamination recommendations for CNS Drugs. Br J Clin Pharmacol 2009; 67: 83-87.
10. Panagiotou OA, Contopoulos-Ioannidis DG, Papanikolaou PN, et al. Different black box warning labeling for same-class drugs. J Gen Intern Med 2011; 26: 603-610.
11. Garbe E, Andersohn F Contraindication labelling changes in the United States and Germany. Eur J Clin Pharmacol 2007; 63: 87-93.
12. Maxwell S, Eichler HG, Bucsics A, et al. e-SPC-delivering drug information in the 21st century: developing new approaches to deliver drug information to prescribers. Br J Clin Pharmacol 2012; 73: 12-15.